Study guide
1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk
Key Takeaways Explain This Topic AI
Cell-free DNA detects more than 99 percent of Trisomy 21 cases but remains a screening test, so every positive result requires confirmation by chorionic villus sampling or amniocentesis.
On a quad screen, Trisomy 21 shows elevated hCG and inhibin A with decreased MSAFP and unconjugated estriol, while Trisomy 18 shows all three serum analytes decreased.
The most common cause of an isolated MSAFP of 2.5 multiples of the median or higher is inaccurate gestational dating, so the first step is a diagnostic ultrasound.
Chorionic villus sampling is performed at 10 0/7 to 13 6/7 weeks and cannot detect neural tube defects; amniocentesis from 15 0/7 weeks adds amniotic fluid AFP and acetylcholinesterase.
Unsensitized Rh-negative patients receive 300 mcg RhD immune globulin immediately after chorionic villus sampling or amniocentesis.
Last updated: September 2026
Genetic Screening vs. Diagnostic Testing
Per ACOG Practice Bulletin 226 and ACNM guidelines, all pregnant patients must be offered both prenatal aneuploidy screening and invasive diagnostic testing , regardless of maternal age. Midwives provide balanced, non-directive counseling respecting patient autonomy.
Aneuploidy Screening Modalities Comparison
Screening Method Window (Weeks) Analytes / Markers Measured Aneuploidies Screened Sensitivity for Trisomy 21 Key Clinical Limitations
Cell-Free DNA (cfDNA / NIPT) ≥10 0/7 weeks to term Placental trophoblastic fragments in maternal circulation Trisomies 21, 18, 13; sex chromosome aneuploidies >99% Screening test only; false positives occur due to confined placental mosaicism, maternal copy number variants, or vanishing twin. Low fetal fraction (<4%) yields "no-call."
First-Trimester Combined 11 0/7 to 13 6/7 weeks Nuchal Translucency (NT) + PAPP-A + hCG Trisomies 21, 18 85–88% Requires certified NT sonographer. Does not screen for neural tube defects.
Second-Trimester Quad Screen 15 0/7 to 22 6/7 weeks (optimal 16–18w) MSAFP + hCG + unconjugated estriol (uE3) + dimeric inhibin A (DIA) Trisomies 21, 18; Open Neural Tube Defects (ONTDs) 80–83% Lower sensitivity than cfDNA; relies strictly on accurate gestational dating.
Interpreting Serum Screening Patterns
Trisomy 21 (Down Syndrome) on Quad Screen: The mnemonic "HI" indicates H CG and I nhibin A are Elevated , while MSAFP and unconjugated estriol (uE3) are Decreased .
Trisomy 18 (Edwards Syndrome) on Quad Screen: All three serum analytes (MSAFP, hCG, uE3) are Decreased , with inhibin A low or normal.
Isolated Elevated MSAFP (≥2.5 Multiples of the Median [MoM]): Associated with open neural tube defects (anencephaly, spina bifida), abdominal wall defects (gastroschisis, omphalocele), multifetal gestation, placental abruption, and fetal demise.
First Step: The most common cause of an aberrant MSAFP is inaccurate gestational dating . The midwife must immediately order a diagnostic ultrasound to confirm gestational age, evaluate fetal viability, exclude twins, and visualize the fetal spine and cranium.
Carrier Screening Guidelines
Universal Carrier Screening: All pregnant individuals should be offered carrier screening for Cystic Fibrosis (CFTR gene) and Spinal Muscular Atrophy (SMA, SMN1 gene), along with a CBC to screen for hemoglobinopathies.
Hemoglobinopathy Workup: If the red blood cell mean corpuscular volume (MCV) is <80 fL in the absence of iron deficiency, obtain a hemoglobin electrophoresis to detect sickle cell trait/disease, hemoglobin C, or beta-thalassemia. For alpha-thalassemia trait (common in Southeast Asian, Mediterranean, and African ancestries), normal electrophoresis requires alpha-globin gene deletion DNA testing.
Invasive Diagnostic Testing Procedures
Diagnostic testing provides definitive fetal karyotype or chromosomal microarray analysis (CMA).
Chorionic Villus Sampling (CVS):
Timing: 10 0/7 to 13 6/7 weeks .
Method: Transcervical or transabdominal aspiration of placental trophoblast tissue under continuous ultrasound guidance.
Advantages: First-trimester definitive genetic results; allows earlier, safer termination if chosen.
Disadvantages & Risks: Cannot assess for neural tube defects (does not sample amniotic fluid AFP); procedural pregnancy loss risk is approximately 0.1% to 0.2% (1 in 500 to 1,000) in experienced centers. If performed prior to 10 0/7 weeks, carries a documented risk of fetal transverse limb reduction defects .
Amniocentesis:
Timing: 15 0/7 to 20+ weeks .
Method: Transabdominal aspiration of 15–20 mL of amniotic fluid containing desquamated fetal amniocytes.
Advantages: Definitive genetic testing (karyotype/microarray) plus diagnostic assessment of Amniotic Fluid Alpha-Fetoprotein (AFAFP) and Acetylcholinesterase (AChE) to diagnose open neural tube defects.
Disadvantages & Risks: Procedure loss rate is approximately 0.1% (1 in 1,000). Transient vaginal spotting or amniotic fluid leakage occurs in 1–2%.
Midwifery Rule: Administer 300 mcg RhD immune globulin to all unsensitized Rh-negative patients immediately following CVS or amniocentesis.
Hereditary Cancer Risk Assessment
The same visit that covers aneuploidy and carrier screening is where hereditary cancer risk is captured, because the blueprint expects the midwife to screen for genetic carrier trait and hereditary cancer testing by personal and family history.
Take a three-generation pedigree covering both maternal and paternal lineages: cancer type, age at diagnosis, bilateral or multifocal disease, and ancestry.
Red flags for hereditary breast and ovarian cancer syndrome (BRCA1/BRCA2): breast cancer before age 50, triple-negative breast cancer before 60, ovarian, fallopian tube, or primary peritoneal cancer at any age, male breast cancer, pancreatic or metastatic prostate cancer, two or more primaries in one person, and Ashkenazi Jewish ancestry with any of these.
Red flags for Lynch syndrome: colorectal or endometrial cancer before age 50, multiple Lynch-spectrum cancers (colorectal, endometrial, ovarian, gastric, urothelial), or a known family mutation.
The USPSTF gives a B recommendation to assessing women with a personal, family, or ancestry-associated risk of BRCA1/2 mutations with a brief familial risk tool, and referring those who screen positive for genetic counseling and, if indicated, testing.
Refer positives to a genetics professional rather than ordering a multigene panel directly; results drive surveillance, risk-reducing surgery, and cascade testing of relatives.